Combined Y-90 SIRT + SBRT for Liver Cancer
Trial Summary
What is the purpose of this trial?
This study will investigate the combination of Ytrium-90 (Y-90) Selective Internal Radiation Therapy (SIRT) followed by Stereotactic Body Radiation Therapy (SBRT). Y-90 SIRT alone or SBRT alone are standard procedures used in the treatment of liver cancer. This study will assess the combination of Y-90 SIRT and SBRT and obtain preliminary information about the side effects and safety of the combination therapy. Additionally, this is the first time that Y-90 PET-CT imaging will be included in planning for SBRT.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of this treatment for liver cancer?
Research shows that selective internal radiation therapy (SIRT) with yttrium-90 can improve outcomes for patients with inoperable liver cancer, including hepatocellular carcinoma (HCC). In one case, a patient with HCC experienced a dramatic response to SIRT after other treatments failed, highlighting its potential effectiveness.12345
Is the combination of Y-90 SIRT and SBRT safe for liver cancer treatment?
Yttrium-90 selective internal radiation therapy (Y-90 SIRT) has been used safely in treating liver cancers like hepatocellular carcinoma and intrahepatic cholangiocarcinoma, with safety confirmed over two decades of clinical use. It is important to have a multidisciplinary team to manage the treatment and monitor for any adverse reactions or complications.678910
What makes the Y-90 SIRT + SBRT treatment for liver cancer unique?
The Y-90 SIRT + SBRT treatment is unique because it combines selective internal radiation therapy (SIRT) with Yttrium-90, which targets liver tumors directly through the bloodstream, with stereotactic body radiation therapy (SBRT), a precise form of external radiation. This combination aims to enhance the effectiveness of treatment by delivering high doses of radiation directly to the tumor while minimizing damage to surrounding healthy tissue.457911
Research Team
Kyle C. Cuneo
Principal Investigator
University of Michigan Rogel Cancer Center
Eligibility Criteria
This trial is for adults with unresectable hepatocellular carcinoma (liver cancer) that meets specific imaging criteria, has a life expectancy of at least 6 months, and agrees to use contraception. It excludes those who can't stay still for scans, are pregnant or refuse birth control, have certain allergies or contraindications to MRI contrast agents or Theraspheres, high bilirubin levels, main portal vein occlusion, excessive lung shunting from the liver.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Y-90 SIRT Treatment
Participants receive Y-90 Selective Internal Radiation Therapy (SIRT) to deliver radiation internally to the tumor
SBRT Treatment
Participants receive Stereotactic Body Radiation Therapy (SBRT) targeting areas of tumors not fully treated by Y-90 SIRT
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessment of overall survival and progression
Treatment Details
Interventions
- PET/CT
- Selective Internal Radiation Therapy
- Stereotactic Body Radiation Therapy
- Yttrium-90
Yttrium-90 is already approved in United States, European Union for the following indications:
- Hepatocellular carcinoma
- Colorectal cancer liver metastases
- Hepatocellular carcinoma
- Colorectal cancer liver metastases
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Michigan Rogel Cancer Center
Lead Sponsor
National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Collaborator
Department of Health and Human Services
Collaborator